BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Yan G, Zhang M, Liu Y, Yin M. Efficacy of vortioxetine combined cognitive behaviour intervention therapy on brain-derived neurotrophic factor level on depressive patients. Psychogeriatrics 2019;19:475-81. [PMID: 30780196 DOI: 10.1111/psyg.12426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
2 Zhou XB, Gu JM, Sun MY, Hu XR, Wu SX. Crystal structures of vortioxetine and its methanol monosolvate. Acta Crystallogr E Crystallogr Commun 2015;71:883-5. [PMID: 26396746 DOI: 10.1107/S2056989015012256] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Bronson J, Black A, Dhar M, Ellsworth B, Robert Merritt J. To Market, To Market—2013. Elsevier; 2014. pp. 437-508. [DOI: 10.1016/b978-0-12-800167-7.00027-4] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Olivier B. Serotonin: a never-ending story. Eur J Pharmacol 2015;753:2-18. [PMID: 25446560 DOI: 10.1016/j.ejphar.2014.10.031] [Cited by in Crossref: 137] [Cited by in F6Publishing: 113] [Article Influence: 19.6] [Reference Citation Analysis]
5 Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2014;10:721-46. [PMID: 24494611 DOI: 10.1517/17425255.2014.885504] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
6 Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Med Chem 2015;7:2385-406. [PMID: 26619226 DOI: 10.4155/fmc.15.134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
7 Kumar RR, Sahu B, Pathania S, Singh PK, Akhtar MJ, Kumar B. Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure-Activity Relationships. ChemMedChem 2021;16:1878-901. [PMID: 33751807 DOI: 10.1002/cmdc.202100045] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Grant JE, Valle S, Cavic E, Redden SA, Chamberlain SR. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Int J Eat Disord 2019;52:786-94. [PMID: 30938842 DOI: 10.1002/eat.23078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs 2015;20:393-406. [PMID: 26012843 DOI: 10.1517/14728214.2015.1049996] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
10 Chin CN, Zain A, Hemrungrojn S, Ung EK, Kwansanit P, Au Yong KC, Chong MSW, Inpa C, Yen TH, Yeoh BBD, Tay LK, Bernardo C, Lim LC, Yap CH, Fones C, Nayak A, Nelleman L. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin 2018;34:1975-84. [PMID: 29768955 DOI: 10.1080/03007995.2018.1477746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Martis LS, Højgaard K, Holmes MC, Elfving B, Wiborg O. Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task. Sci Rep 2021;11:9113. [PMID: 33907240 DOI: 10.1038/s41598-021-88462-7] [Reference Citation Analysis]
12 Zheng J, Wang Z, Li E. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis. Afr Health Sci 2019;19:1716-26. [PMID: 31149002 DOI: 10.4314/ahs.v19i1.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40:174-86. [PMID: 25350320 DOI: 10.1503/jpn.140120] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
14 Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. J Clin Psychopharmacol 2018;38:172-9. [DOI: 10.1097/jcp.0000000000000861] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Dhir A, Sarvaiya J. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert Rev Neurother 2014;14:1349-63. [PMID: 25418918 DOI: 10.1586/14737175.2014.987131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. [PMID: 25643025 DOI: 10.1037/a0038550] [Cited by in Crossref: 172] [Cited by in F6Publishing: 140] [Article Influence: 28.7] [Reference Citation Analysis]
17 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
18 Huang Y, Zheng S, Pan Y, Li T, Xu Z, Shao M. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC–MS/MS: Application to their pharmacokinetic interaction study. Journal of Pharmaceutical and Biomedical Analysis 2016;128:184-90. [DOI: 10.1016/j.jpba.2016.05.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
19 Guan S, Zou Y, Jia B, Wu L, Yang Z, Yuan F, Zhang L. Pharmacokinetic and metabolic studies of Vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. J Sep Sci 2018;41:4469-79. [DOI: 10.1002/jssc.201800607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
20 Qin M, Qiao H, Yuan Y, Shao Q. A quantitative LC-MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to a toxicokinetic study. Anal Methods 2018;10:1023-31. [DOI: 10.1039/c7ay02642k] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Mahnashi MH. Synthesis of three-dimensional nickel ferrite nanospheres decorated activated graphite nanoplatelets for electrochemical detection of vortioxetine with pharmacokinetic insights in human volunteers. Mikrochim Acta 2020;187:519. [PMID: 32852618 DOI: 10.1007/s00604-020-04523-0] [Reference Citation Analysis]
22 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
23 Zhou X, Hu X, Wu S, Ye J, Sun M, Gu J, Zhu J, Zhang Z. Structures and physicochemical properties of vortioxetine salts. Acta Crystallogr B Struct Sci Cryst Eng Mater 2016;72:723-32. [DOI: 10.1107/s2052520616010556] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]